Blog | HemaCare

HemaCare Bone Marrow Tissue Boosts Development of Cell Therapy for Sickle Cell Disease

Dec 12, 2018 10:10:00 AM / by Nancy Andon, MSc posted in bone marrow, bone marrow-derived stem cells, sickle cell disease

0 Comments

An independent study cites the use of HemaCare-sourced human bone marrow-derived CD34+ stem cells for research into a potential new therapy for sickle cell disease. [1]

Sickle cell is a serious disease that affects millions of people throughout the world. People affected by sickle cell anemia have rigid, sickle-shaped red blood cells that can’t adequately carry oxygen to the body’s tissues. As a result, sickle cell patients suffer from a variety of medical complications, which can shorten their life span. Contemporary cell therapy treatments have focused on a gene therapy approach that uses lentiviral vectors to supply CD34+ bone marrow-derived stem cells with an unimpaired version of the hemoglobin gene. While this tactic has met with some promise, finding healthy, matched bone marrow donors is difficult. Researchers at Biogen, a well-known biotech firm headquartered in Cambridge, Massachusetts, are trying to discover cell and gene therapy methods that they hope will provide an alternative solution, and thereby improve treatment success rates.

Read More

Progress in Sickle Cell Cure Research

Mar 26, 2018 10:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in cd 34 stem cells, CD34, disease-state products, sickle cell disease

0 Comments

The findings of a new study on sickle cell disease may lead to a new era in the approach to treatment.

Sickle cell disease (often referred to as sickle cell anemia) is a group of blood disorders in which the blood cells have an abnormal sickle shape instead of the biconcave disk shape. The sickle-shaped cells have a shorter life span (leading to anemia), but they also block normal blood flow leading to pain and organ dysfunction. There is no cure, and treatments that exist are aimed to control symptoms and related complications.

Read More

Gene Therapy Tackles Sickle-Cell Disease

Jan 8, 2018 10:25:00 AM / by Stacy Matthews Branch, DVM, PhD posted in gene therapy, sickle cell disease

0 Comments

Sickle cell disease (SCD) is a genetic disorder that affects red blood cells. This disease affects people of color more commonly and is due to the effect of abnormally shaped red blood cells (crescent or sickle-shaped instead of disc shaped). The misshapen red blood cells contain a form of hemoglobin, hemoglobin S, resulting from mutation of the beta-globin gene. Hemoglobin S does not hold oxygen efficiently, and the abnormal shape of the red blood cells prevents normal flow through the blood vessels, leading to vessel blockage. This leads to the pain and tissue damage seen in patients with SCD.

Read More

Patient with Sickle Cell Disease Responds Favorably to Gene Therapy

Apr 11, 2017 11:01:21 AM / by Stacy Matthews Branch, DVM, PhD posted in Hematopoietic History, biomedical research, cd 34 stem cells, research, sickle cell disease, Stem Cell Therapy

0 Comments

Sickle cell disease refers to a group of genetic blood disorders mainly affecting people of African, Mediterranean, Middle Eastern, and Caribbean decent. Those with sickle cell disease carry the abnormal hemoglobin S in their red blood cells due to a mutation of the β-globin gene. Instead of having flexible, disc-shaped red blood cells, affected individuals have characteristic sickle-shaped, more rigid cells that cause disturbances in blood flow and tissue oxygenation.

Read More

New Drug for Sickle Cell Disease Targets Leukocytes

Apr 15, 2015 1:00:12 PM / by Daisy posted in GMI-1070, clinical trial, red blood cell, research, sickle cell disease

0 Comments

Leukocytes adhere to blood vessels as a mechanism to enter tissue where there is inflammation. Inadvertently, they pile up sickle cell red blood cells.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts